New developments and directions in the clinical application of the echinocandins

@article{Chang2016NewDA,
  title={New developments and directions in the clinical application of the echinocandins},
  author={C. C. Chang and Monica A. Slavin and Sharon C.-A. Chen},
  journal={Archives of Toxicology},
  year={2016},
  volume={91},
  pages={1613-1621}
}
AbstractThe echinocandins—caspofungin, anidulafungin and micafungin—are semi-synthetic cyclic hexapeptide antimicrobial agents with modified N-linked acyl lipid side chains which anchor the compounds to the phospholipid bilayer of the fungal cell membrane, thereby inhibiting synthesis of fungal cell wall glucan. Over the last 10 years, echinocandins have become the first-line antifungal treatment of candidaemia and other forms of invasive candidiasis (IC). Echinocandins are generally well… Expand
The synthesis and activity evaluation of N‐acylated analogs of echinocandin B with improved solubility and lower toxicity
  • Bing Zhu, Yuanzhen Dong, +4 authors Jun Feng
  • Medicine, Chemistry
  • Journal of peptide science : an official publication of the European Peptide Society
  • 2020
TLDR
Compared with anidulafungin, compound 5 showed a comparable fungicidal effect, much higher solubility, and lower toxicity, and has the potential for further research and development on account of reserved antifungal activity, high solubilities, and low toxicity. Expand
Susceptibility of Candida glabrata biofilms to echinocandins: alterations in the matrix composition
TLDR
The data suggest that, generally, after contact with echinocandins, the concentration of β-1,3 glucans increased, and adjustments in the matrix composition of C. glabrata biofilms seem responsible and may determine the effectivity of the drug responses. Expand
Micafungin Enhances the Human Macrophage Response to Candida albicans through β-Glucan Exposure
TLDR
The results strongly suggest that in C. albicans treatment with micafungin, in addition to having the expected toxic antifungal effect, it potentiates the immune response, improving the interaction and activation of human macrophages, probably through the unmasking of β-glucans on the cell wall surface. Expand
BG 40018 : a promising drug candidate for the treatment of invasive fungal infections
Objective: BG40018 is a semisynthetic echinocandin derived from anidulafungin. This study was conducted to evaluate the pharmacokinetics and efficacy of BG40018. Methods: The in vitro antifungalExpand
Drugs currently under investigation for the treatment of invasive candidiasis
TLDR
This paper explores investigational agents for the treatment of invasive candidiasis, with particular attention paid to compounds that have recently entered phase I or phase II clinical trials. Expand
Drug repurposing strategies in the development of potential antifungal agents
TLDR
This review of currently used antifungal agents highlights the most up-to-date information on the effectiveness of existing drugs with antIFungal activity and the ant ifungal mechanisms ofexisting drugs are highlighted. Expand
Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies
TLDR
Echinocandins are a reasonable alternative to azoles and other agents for antifungal prophylaxis in patients undergoing intensive chemotherapy for haematological malignancy or those receiving HCT, excluding those with significant GvHD. Expand
Antifungal drugs: New insights in research & development.
TLDR
The development of antifungal drugs focusing on the approach of drug repurposing and the search for novel drugs for classical targets, the most recently described gene targets for drug development, the possibilities of immunotherapy using antibodies, cytokines, therapeutic vaccines and antimicrobial peptides are discussed. Expand
Drug development challenges and strategies to address emerging and resistant fungal pathogens
TLDR
This paper examines both challenges and opportunities associated with antifungal drug development and explores potential avenues to accelerate the development pipeline, including data sharing, surrogate endpoints, and the role of historical controls in clinical trials. Expand
The Patenting and Technological Trends in Candidiasis Treatment: A Systematic Review (2014-2018).
TLDR
This study evaluated the development of new drugs, formulations, as well as patents for the treatment of infections caused by Candida spp. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 92 REFERENCES
Echinocandin antifungal drugs
TLDR
Results of studies of caspofungin in candidaemia and invasive candidiasis suggest equivalent efficacy to amphotericin B, with substantially fewer toxic effects, suggests that combination antifungal therapy could become a general feature of the echinocandins. Expand
CD101: a novel long‐acting echinocandin
TLDR
Collectively, CD101 has great potential not only in treating invasive Candida infections but also in preventing emergence of resistance to currently approved echinocandin drugs. Expand
Impact of special patient populations on the pharmacokinetics of echinocandins
TLDR
This review provides up-to-date information on PK data of anidulafungin, caspofungin and micaf ungin in special patient populations, including neonates, children and adolescents, obese patients, patients with hepatic or renal impairment, critically ill patients (including burn patients) and patients with hematological diseases. Expand
Echinocandin Resistance in Candida.
  • D. Perlin
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2015
TLDR
The mechanism of echinocandin resistance involves amino acid changes in "hot spot" regions of FKS-encoded subunits of glucan synthase, which decreases the sensitivity of enzyme to drug, resulting in higher minimum inhibitory concentration values. Expand
COMPARISON OF CASPOFUNGIN AND AMPHOTERICIN B FOR INVASIVE CANDIDIASIS
A BSTRACT Background Caspofungin is an echinocandin agent with fungicidal activity against candida species. We performed a double-blind trial to compare caspofungin with amphotericin B deoxycholateExpand
Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults
TLDR
CD101 IV was safe and well tolerated at single and multiple doses of up to 400 mg given once weekly for 3 weeks and exhibited a long t1/2, minimal accumulation over several weeks, negligible renal excretion, and high plasma exposures enabling once-weekly dosing. Expand
In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species
TLDR
The results suggest that current susceptibility breakpoints and the consideration of organism species in these determinations should be reexplored. Expand
Potential Microbiological Effects of Higher Dosing of Echinocandins.
TLDR
Understanding the specific actions of echinocandins is paramount to optimizing their use at either standard or higher dosing schemes, as well as developing future improvements in the antifungal arsenal. Expand
Single or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna!
  • T. Gumbo
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2015
TLDR
Human pharmacokinetics/pharmacodynamics studies confirmed this link between micafungin efficacy and the ratio of the area under the concentration-time curve, and the optimal exposures initially identified in neutropenic animals. Expand
Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species
ABSTRACT CD101 is a novel echinocandin with a long half-life undergoing clinical development for treatment of candidemia/invasive candidiasis and vulvovaginal candidiasis. The potential for andExpand
...
1
2
3
4
5
...